

---

## **Rakovina Therapeutics Inc. Appoints Biotechnology Industry Veteran Julie M. Cherrington, PhD to Board of Directors**

**April 5, 2021, Vancouver, British Columbia:** Rakovina Therapeutics Inc. (the “Company”) (TSX-V: **RKV**) is pleased to announce the appointment of Julie M. Cherrington, PhD to the Company’s Board of Directors.

“We are delighted to welcome Dr. Cherrington to the Rakovina Therapeutics team,” said Mr. Jeffrey Bacha, Rakovina Therapeutics’ executive chairman. “The addition of an executive leader with Dr. Cherrington’s experience and talent to our Board of Directors will greatly benefit Rakovina Therapeutics as we advance our pipeline of novel anti-cancer agents toward human clinical trials.”

Julie M. Cherrington is an accomplished life science executive with a record of demonstrated success in advancing drug candidates into human clinical trials and through to commercialization. She has been a key contributor to the successful development of multiple FDA-approved products, including the anti-cancer agents SUTENT® and PALLADIA® and the anti-viral agents VISTIDE®, VIREAD®, and HEPSERA®.

Dr. Cherrington has served as President and Chief Executive Officer at several oncology companies, including Arch Oncology, Revitope Oncology, Zenith Epigenetics, and Pathway Therapeutics. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. She has previously served on the Boards of Directors of Chemgenex, Progen, Xenome, and Leading Biosciences. She currently serves on the Boards of both QUE Oncology and Mirati Therapeutics.

She also serves on the Scientific Advisory Board of the Clarity Foundation and is an advisor in several entrepreneurship initiatives including the California Life Sciences Institute (CLSI), UC San Francisco, Stanford, UC Davis, and Equalize 2020 and 2021.

Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

In association with this appointment, the Company has granted Dr. Cherrington incentive stock options to purchase up to an aggregate of 125,000 common shares at \$0.20 per share for a period of 5 years expiring March 31, 2026.

### **About Rakovina Therapeutics Inc.**

Rakovina Therapeutics Inc. was established in 2020 to develop new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Further information may be found at [www.rakovinatherapeutics.com](http://www.rakovinatherapeutics.com).

### ***Additional Information***

*The TSXV has in no way passed upon the merits of the Qualifying Transaction and has neither approved nor disapproved the content of this press release. Neither the TSXV nor its Regulation Services Provider*

(as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Notice regarding forward-looking statements:

*This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company’s most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company’s profile page at [www.sedar.com](http://www.sedar.com).*

Contact:

**Rakovina Therapeutics Inc.**

David Hyman

Chief Financial Officer

Email: [info@rakovinatherapeutics.com](mailto:info@rakovinatherapeutics.com)

**Investor Relations Contact**

[IR@rakovinatherapeutics.com](mailto:IR@rakovinatherapeutics.com)

**Media Contact**

[MEDIA@rakovinatherapeutics.com](mailto:MEDIA@rakovinatherapeutics.com)